Rep. Julie Johnson Sells Abbott Laboratories (NYSE:ABT) Stock

Representative Julie Johnson (D-Texas) recently sold shares of Abbott Laboratories (NYSE:ABT). In a filing disclosed on September 11th, the Representative disclosed that they had sold between $1,001 and $15,000 in Abbott Laboratories stock on August 14th. The trade occurred in the Representative’s “CHASE BROKERAGE ACCOUNT (3935)” account.

Representative Julie Johnson also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of McDonald’s (NYSE:MCD) on 8/14/2025.
• Sold $1,001 – $15,000 in shares of Eli Lilly and Company (NYSE:LLY) on 8/14/2025.
• Sold $1,001 – $15,000 in shares of Arthur J. Gallagher & Co. (NYSE:AJG) on 8/14/2025.
• Sold $1,001 – $15,000 in shares of Parker-Hannifin (NYSE:PH) on 8/14/2025.
• Sold $1,001 – $15,000 in shares of Charles Schwab (NYSE:SCHW) on 8/14/2025.
• Sold $1,001 – $15,000 in shares of Fidelity National Information Services (NYSE:FIS) on 8/14/2025.
• Sold $1,001 – $15,000 in shares of ConocoPhillips (NYSE:COP) on 8/14/2025.
• Sold $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 8/14/2025.
• Sold $1,001 – $15,000 in shares of Dover (NYSE:DOV) on 8/14/2025.
• Sold $1,001 – $15,000 in shares of UnitedHealth Group (NYSE:UNH) on 8/14/2025.

Abbott Laboratories Stock Performance

ABT stock opened at $134.67 on Friday. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30. Abbott Laboratories has a fifty-two week low of $110.86 and a fifty-two week high of $141.23. The stock has a market capitalization of $234.39 billion, a PE ratio of 16.88, a price-to-earnings-growth ratio of 2.54 and a beta of 0.69. The company has a 50 day moving average price of $130.38 and a 200 day moving average price of $131.20.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, hitting analysts’ consensus estimates of $1.26. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The firm had revenue of $11.14 billion during the quarter, compared to analyst estimates of $11.01 billion. During the same quarter in the previous year, the business earned $1.14 EPS. The business’s quarterly revenue was up 7.4% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Analysts forecast that Abbott Laboratories will post 5.14 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. IMG Wealth Management Inc. grew its position in Abbott Laboratories by 759.1% in the 2nd quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock valued at $26,000 after purchasing an additional 167 shares during the period. Hughes Financial Services LLC bought a new position in Abbott Laboratories in the 1st quarter valued at about $27,000. Abound Financial LLC acquired a new position in Abbott Laboratories during the 1st quarter valued at about $28,000. Elequin Capital LP bought a new stake in Abbott Laboratories during the 1st quarter worth approximately $30,000. Finally, Wormser Freres Gestion purchased a new stake in shares of Abbott Laboratories in the fourth quarter worth approximately $32,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have commented on ABT shares. BTIG Research cut their target price on Abbott Laboratories from $148.00 to $145.00 and set a “buy” rating on the stock in a research note on Friday, July 18th. William Blair raised Abbott Laboratories to a “strong-buy” rating in a research report on Thursday, July 17th. Morgan Stanley increased their price target on shares of Abbott Laboratories from $127.00 to $137.00 and gave the company an “equal weight” rating in a report on Tuesday, July 15th. Royal Bank Of Canada upped their target price on Abbott Laboratories from $145.00 to $147.00 and gave the company an “outperform” rating in a research report on Tuesday, July 15th. Finally, Evercore ISI lifted their price target on Abbott Laboratories from $140.00 to $145.00 and gave the stock an “outperform” rating in a report on Tuesday, July 8th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $145.22.

Insider Transactions at Abbott Laboratories

In related news, CFO Philip P. Boudreau sold 5,550 shares of the stock in a transaction on Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the completion of the sale, the chief financial officer directly owned 51,003 shares of the company’s stock, valued at approximately $6,862,453.65. This represents a 9.81% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 0.46% of the company’s stock.

About Representative Johnson

Julie Johnson (Democratic Party) is a member of the U.S. House, representing Texas’ 32nd Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

Johnson (Democratic Party) ran for election to the U.S. House to represent Texas’ 32nd Congressional District. She won in the general election on November 5, 2024.

Julie Johnson earned a B.A. in history and government from the University of Texas at Austin in 1987 and a J.D. from the University of Houston Law Center in 1991. Johnson’s career experience includes working as an attorney.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.